Building on a report released in The Lancet Neurology in 2007, an international group of dementia experts is proposing a change in the criteria used to determine whether a patient has Alzheimer’s disease.  According to the study, “[d]istinctive and reliable biomarkers of Alzheimer’s Disease are now available through structural MRI, molecular neuroimaging with PET, and cerebrospinal fluid analyses”.  These biomarkers can identify the disease roughly 10 years before symptoms of Alzheimer’s disease manifest themselves.  As a result, the researchers are proposing a revised set of parameters for diagnosing the disease based on the use of these biomarkers.   They argue that these procedures  will help diagnose and treat Alzheimers during the pre-clinical stage, which is the best time to begin interventional treatments that could help reduce the disease’s impact.

For more information, visit:


Medical News